Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition
Xiaofeng Jiang, Jun Zhou, Anita Giobbie‐Hurder, et al.
Clinical Cancer Research (2012) Vol. 19, Iss. 3, pp. 598-609
Open Access | Times Cited: 441

Showing 1-25 of 441 citing articles:

Regulation and Function of the PD-L1 Checkpoint
Chong Sun, Riccardo Mezzadra, Ton N. Schumacher
Immunity (2018) Vol. 48, Iss. 3, pp. 434-452
Open Access | Times Cited: 1825
Combination cancer immunotherapy and new immunomodulatory targets
Kathleen M. Mahoney, Paul D. Rennert, Gordon J. Freeman
Nature Reviews Drug Discovery (2015) Vol. 14, Iss. 8, pp. 561-584
Closed Access | Times Cited: 1200
Mechanisms Controlling PD-L1 Expression in Cancer
Jong‐Ho Cha, Li-Chuan Chan, Chia‐Wei Li, et al.
Molecular Cell (2019) Vol. 76, Iss. 3, pp. 359-370
Open Access | Times Cited: 746
Regulation of PD-L1: a novel role of pro-survival signalling in cancer
Jiezhong Chen, Chen Chen Jiang, Lei Jin, et al.
Annals of Oncology (2015) Vol. 27, Iss. 3, pp. 409-416
Open Access | Times Cited: 689
Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer
Kristin J. Lastwika, Willie Wilson, Qing Kay Li, et al.
Cancer Research (2015) Vol. 76, Iss. 2, pp. 227-238
Open Access | Times Cited: 688
CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients
Patrick A. Ott, F. Stephen Hodi, Caroline Robert
Clinical Cancer Research (2013) Vol. 19, Iss. 19, pp. 5300-5309
Closed Access | Times Cited: 659
Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation
Nan Chen, Wenfeng Fang, Jianhua Zhan, et al.
Journal of Thoracic Oncology (2015) Vol. 10, Iss. 6, pp. 910-923
Open Access | Times Cited: 608
Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth
Sonja Kleffel, Christian Posch, Steven R. Barthel, et al.
Cell (2015) Vol. 162, Iss. 6, pp. 1242-1256
Open Access | Times Cited: 589
Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA
Matthew A. Coelho, Sophie de Carné Trécesson, Sareena Rana, et al.
Immunity (2017) Vol. 47, Iss. 6, pp. 1083-1099.e6
Open Access | Times Cited: 529
Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF V600E melanoma
Siwen Hu‐Lieskovan, Stephen Mok, Blanca Homet Moreno, et al.
Science Translational Medicine (2015) Vol. 7, Iss. 279
Open Access | Times Cited: 518
Regulation of PD-L1 expression in the tumor microenvironment
Ming Yi, Mengke Niu, Linping Xu, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 449
IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer
Thomas A. Mace, Reena Shakya, Jason R. Pitarresi, et al.
Gut (2016) Vol. 67, Iss. 2, pp. 320-332
Open Access | Times Cited: 445
PD‐1/PD‐L1 immune checkpoint: Potential target for cancer therapy
Fatemeh Karimi Dermani, Pouria Samadi, Golebagh Rahmani, et al.
Journal of Cellular Physiology (2018) Vol. 234, Iss. 2, pp. 1313-1325
Closed Access | Times Cited: 413
Induction of PD-L1 Expression by the EML4–ALK Oncoprotein and Downstream Signaling Pathways in Non–Small Cell Lung Cancer
Keiichi Ota, Koichi Azuma, Akihiko Kawahara, et al.
Clinical Cancer Research (2015) Vol. 21, Iss. 17, pp. 4014-4021
Open Access | Times Cited: 412
The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4
Li Liu, Patrick A. Mayes, Stephen D. Eastman, et al.
Clinical Cancer Research (2015) Vol. 21, Iss. 7, pp. 1639-1651
Open Access | Times Cited: 410
Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond
Luoyan Ai, Antao Xu, Jie Xu
Advances in experimental medicine and biology (2020), pp. 33-59
Closed Access | Times Cited: 385
Mechanisms regulating PD-L1 expression on tumor and immune cells
Shuming Chen, George A. Crabill, Theresa S. Pritchard, et al.
Journal for ImmunoTherapy of Cancer (2019) Vol. 7, Iss. 1
Open Access | Times Cited: 371
BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice
Chengwen Liu, Weiyi Peng, Chunyu Xu, et al.
Clinical Cancer Research (2012) Vol. 19, Iss. 2, pp. 393-403
Open Access | Times Cited: 359
PD-L1 Distribution and Perspective for Cancer Immunotherapy—Blockade, Knockdown, or Inhibition
Yilun Wu, Weiyu Chen, Zhi Ping Xu, et al.
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 355
Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
Hao Zhang, Ziyu Dai, Wantao Wu, et al.
Journal of Experimental & Clinical Cancer Research (2021) Vol. 40, Iss. 1
Open Access | Times Cited: 353
Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics
Hirohito Yamaguchi, Jung-Mao Hsu, Wenhao Yang, et al.
Nature Reviews Clinical Oncology (2022) Vol. 19, Iss. 5, pp. 287-305
Closed Access | Times Cited: 331
The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?
Daniel Sanghoon Shin, Antoni Ribas
Current Opinion in Immunology (2015) Vol. 33, pp. 23-35
Closed Access | Times Cited: 328
Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma
Mohammad Atefi, Earl Avramis, Amanda Lassen, et al.
Clinical Cancer Research (2014) Vol. 20, Iss. 13, pp. 3446-3457
Open Access | Times Cited: 310
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Meng‐Ling Wu, Qianrui Huang, Yao Xie, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 299
Intratumoral Copper Modulates PD-L1 Expression and Influences Tumor Immune Evasion
Florida Voli, Emanuele Valli, Luigi Lerra, et al.
Cancer Research (2020) Vol. 80, Iss. 19, pp. 4129-4144
Open Access | Times Cited: 293
Page 1 - Next Page

Scroll to top